| Entry |
|
|---|
| Name |
Bivalirudin (USAN/INN);
Angiomax (TN)
|
|---|
| Product |
|
|---|
| Generic |
BIVALIRUDIN (Accord Healthcare), BIVALIRUDIN (Apotex corp), BIVALIRUDIN (AuroMedics Pharma LLC), BIVALIRUDIN (Cipla USA), BIVALIRUDIN (Dr. Reddy's Laboratories Limited), BIVALIRUDIN (Fresenius Kabi USA), BIVALIRUDIN (Fresenius Kabi USA), BIVALIRUDIN (Hospira), BIVALIRUDIN (Hospira), BIVALIRUDIN (Mylan Institutional LLC), BIVALIRUDIN (Sagent Pharmaceuticals), BIVALIRUDIN (Sandoz), BIVALIRUDIN (Sandoz) |
|---|
| Formula |
C98H138N24O33
|
|---|
| Exact mass |
2178.9858
|
|---|
| Mol weight |
2180.2853
|
|---|
| Sequence |
FPRPGGGGNG DFEEIPEEYL |
|---|
| Type |
Peptide |
|---|
| Class |
|
|---|
| Remark |
| Product (DG02963): | D03136<US> |
|
|---|
| Efficacy |
Anticoagulant, Thrombin inhibitor |
|---|
| Comment |
Peptide
Hirudin derivative
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
| hsa04610 | Complement and coagulation cascades |
|
|---|
| Interaction |
|
|---|
| Structure map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
B BLOOD AND BLOOD FORMING ORGANS
B01 ANTITHROMBOTIC AGENTS
B01A ANTITHROMBOTIC AGENTS
B01AE Direct thrombin inhibitors
B01AE06 Bivalirudin
D03136 Bivalirudin (USAN/INN) <US>
Target-based classification of drugs [BR:br08310]
Not elsewhere classified
Immune system
Complement and coagulation
F2
D03136 Bivalirudin (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
New Molecular Entity and New Therapeutic Biological Product Approvals
D03136
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D03136
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D03136
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
